

Remarks/Arguments

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. In addition the following amendments have been made:


- Claim 2 the missing " ' "s were added to $-NR^{15}R^{16}$, $-NHC(O)NR^{15}R^{16}$, $-C(O)R^{15}$ and $-C(O)OR^{15}$.
- Claims 3, 8 to 11 have been amended to insert the phrase "or a salt or ester thereof". These claims depend on claim 2 and original claim 2 included the language "or a salt or ester thereof".
- Claims 4 to 7 and 12 to 15 have been amended to insert the phrase "or a salt, ester or prodrug thereof". These claims depend on claim 1 and original claim 1 included the language "or a salt, ester or prodrug thereof".
- Claim 10 has been amended to correct a typographical error.
- Claim 12 has been amended to correct a typographical error.
- Claim 16 has been amended to correct a capital "F".
- Claim 23: has been amended to insert the phrase "or a pharmaceutically acceptable salt or ester thereof". Basis for this amendment is to be found on page 91 lines 3-24 of the published PCT specification.
- Claim 26 has been added. This is directed towards a method of treatment. Basis for this claim is to be found at page 92, lines 1-5 of the published PCT specification.

No new matter has been added by these amendments and the above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101015-1P US.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Lucy Padgett", is written over a horizontal line.

Name: Lucy Padgett
Dated: October 7, 2005
Reg. No.: L0074
Phone No.: 781-839-4182

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451